Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare has restructured its partnership with Onyx Pharmaceuticals for the development and marketing of Nexavar (sorafenib) tablets and signed a new deal related to a late-stage oncology compound, regorafenib.
Subscribe to our email newsletter
Nexavar is an oral anti-cancer therapy for liver cancer and for the treatment of patients with advanced kidney cancer
As per the deal, Bayer will have the final decision-making authority for global development and commercialization of regorafenib.
Onyx on the other hand will receive a royalty on any future global net sales of regorafenib.
Onyx CEO N Anthony Coles said the new deal would reinforce the collaboration and provide an opportunity to participate in the market potential of regorafenib.